Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
3E Bioventures Capital is a venture capital fund based in Palo Alto, California, specializing in life sciences. Founded to support global health innovators, the firm manages a portfolio of 30 companies and emphasizes a science-driven investment approach. Their focus includes new drugs, drug discovery platforms, and TechBio innovations.
The firm invests in the biotech sector, particularly in pre-seed, seed, and Series A stages. They target new drug development and drug discovery platforms, as well as TechBio innovations that aim to disrupt existing healthcare paradigms.
Notable portfolio companies include Aravive (Nasdaq: ARAV), a biologic drug targeting tumor metastasis; C4 Therapeutics (Nasdaq: CCCC), known for small-molecule drugs that degrade disease-causing proteins; and Cognition Therapeutics (Nasdaq: CGTX), which focuses on central nervous system disorders. Other companies include OncoImmune, Dermaliq, and ProNovo.
Submit your pitch through their website's contact form for consideration.
Yes, 3E Bioventures often leads investment rounds, particularly in early-stage biotech companies.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and potential in their development.
The specific size of the current fund is not publicly disclosed, but the firm actively manages a diverse portfolio of 30 companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.